Summit TherapeuticsSMMT
SMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 105
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
226% more capital invested
Capital invested by funds: $566M [Q2] → $1.85B (+$1.28B) [Q3]
178% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 23
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
43% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 35
34% more funds holding
Funds holding: 122 [Q2] → 163 (+41) [Q3]
1.33% more ownership
Funds ownership: 10.33% [Q2] → 11.66% (+1.33%) [Q3]
26% less call options, than puts
Call options by funds: $55.9M | Put options by funds: $75.5M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
29%
upside
Avg. target
$33
87%
upside
High target
$44
146%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Wells Fargo Mohit Bansal 28% 1-year accuracy 7 / 25 met price target | 68%upside $30 | Overweight Initiated | 11 Dec 2024 |
Jefferies Brent Thill 75% 1-year accuracy 41 / 55 met price target | 73%upside $31 | Buy Initiated | 6 Dec 2024 |
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 164 met price target | 146%upside $44 | Buy Reiterated | 18 Nov 2024 |
JMP Securities Reni Benjamin 17% 1-year accuracy 6 / 36 met price target | 79%upside $32 | Market Outperform Initiated | 4 Nov 2024 |
Citigroup Yigal Nochomovitz 28% 1-year accuracy 13 / 46 met price target | 29%upside $23 | Neutral Downgraded | 27 Sept 2024 |
Financial journalist opinion
Based on 13 articles about SMMT published over the past 30 days
Positive
The Motley Fool
1 day ago
Where Will Summit Therapeutics Be in 5 Years?
Summit Therapeutics (SMMT 8.36%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023.
Positive
The Motley Fool
1 day ago
3 Stocks That Could Turn $1,000 into $5,000 by 2030
A five-bagger in only five years? Any investor would love to buy such a stock.
Neutral
The Motley Fool
3 days ago
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
Positive
The Motley Fool
6 days ago
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (VKTX -1.75%) and Summit Therapeutics (SMMT -0.22%) more than doubled in 2024.
Positive
The Motley Fool
1 week ago
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Normally, you might expect to achieve significant gains from stocks if you invest in them for years, perhaps decades. But given how hot the stock market has been this year, some stocks have produced life-changing returns in much shorter time frames.
Neutral
Business Wire
1 week ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee.
Positive
Zacks Investment Research
1 week ago
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
Positive
The Motley Fool
2 weeks ago
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Summit Therapeutics (SMMT 5.82%) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its price nearly 6% higher across the day's trading session.
Positive
Seeking Alpha
2 weeks ago
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III results for ivonescimab versus KEYTRUDA in first-line NSCLC are promising, but registration in the US will require completion of HARMONI-7, which has just begun recruiting. Top-line data from the HARMONi trial is expected in mid-2025, potentially leading to FDA approval with complete enrollment as of Q3.
Neutral
The Motley Fool
2 weeks ago
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Do you ever wonder what America's wealthiest stock traders are buying and selling? Thanks to the Securities and Exchange Commission, you don't have to.
Charts implemented using Lightweight Charts™